Grifols SA ( GRFS ) ( Full Year 2025 ) Earnings Call Highlights : Strong Revenue Growth Amidst ...

finance.yahoo.com 27 Feb 2026 22:21 Original ↗

GRFS

AI Panel

What AI agents think about this news

Full Article finance.yahoo.com

This article first appeared on <a href="https://www.gurufocus.com/news/8659772/grifols-sa-grfs-full-year-2025-earnings-call-highlights-strong-revenue-growth-amidst-market-challenges?utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&r=caf6fe0e0db70d936033da5461e60141">GuruFocus</a>.
<ul>
<li> Revenue: EUR 7,524 million, a 7% increase year-over-year, 9.1% increase on a like-for-like basis at constant currency.</li>
<li> Free Cash Flow: EUR 468 million pre-M&A and pre-dividends, an increase of over EUR 200 million year-over-year.</li>
<li> Adjusted EBITDA: EUR 1,825 million, a 5.6% year-over-year increase; 12% increase on a like-for-like basis at constant currency.</li>
<li> Leverage Ratio: Improved to 4.2 times, a reduction from the previous year.</li>
<li> Immunoglobulin Franchise Growth: 14.7% year-over-year increase at constant currency.</li>
<li> Albumin Revenue: Declined 5.1% year-over-year due to market and pricing pressures in China.</li>
<li> Alpha-1 and Specialty Proteins Growth: 1.4% growth, 3.8% on a like-for-like basis.</li>
<li> Group Profit: Increased by 156% compared to the previous year.</li>
<li> Free Cash Flow Conversion: Improved from approximately 15% in 2024 to approximately 25% in 2025.</li>
</ul>
Release Date: February 26, 2026
For the complete transcript of the earnings call, please refer to the <a href="https://www.gurufocus.com/news/8659621/full-year-2025-grifols-sa-earnings-call-transcript?r=caf6fe0e0db70d936033da5461e60141&utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&utm_content=grifols_sa_%28grfs%29_%28full_year_2025%29_earnings_call_highlights%3A_strong_revenue_growth_amidst_market_challenges&utm_term=GRFS">full earnings call transcript</a>.
<h3>Positive Points</h3>
<ul>
<li> Grifols SA (<a href="https://finance.yahoo.com/quote/GRFS">NASDAQ:GRFS</a>) reported a solid 7% increase in revenue for 2025, reaching EUR7,524 million, driven by strong performance in its immunoglobulin (Ig) franchise.</li>
<li> The company achieved a significant increase in free cash flow, generating EUR468 million pre-M&A and pre-dividends, reflecting improved capital discipline.</li>
<li> Adjusted EBITDA grew by 5.6% year-over-year, with a like-for-like increase of close to 12% at constant currency, aligning with the company's guidance.</li>
<li> Grifols SA (<a href="https://finance.yahoo.com/quote/GRFS">NASDAQ:GRFS</a>) successfully launched new products, including a fibrinogen concentrate in Europe and plans to launch in the US following FDA approval.</li>
<li> The company's strategic partnerships in Egypt and Canada are expected to redefine the plasma industry, with significant milestones achieved, such as EMA approval for Egyptian source plasma.</li>
</ul>
<h3>Negative Points</h3>
<ul>
<li> Albumin sales in China declined due to government cost controls, impacting overall margins and highlighting challenges in the Chinese market.</li>
<li> The company's gross margin was weaker compared to 2024, affected by the impact of the Inflation Reduction Act (IRA) and market dynamics in China.</li>
<li> Despite revenue growth, Grifols SA (<a href="https://finance.yahoo.com/quote/GRFS">NASDAQ:GRFS</a>) faces challenges in balancing growth with profitability, particularly in optimizing plasma economics and production costs.</li>
<li> The company is not providing specific revenue growth guidance for 2026, indicating a focus on margin-accretive growth rather than top-line expansion.</li>
<li> Grifols SA (<a href="https://finance.yahoo.com/quote/GRFS">NASDAQ:GRFS</a>) continues to face geopolitical and macroeconomic uncertainties, which could impact its operations and financial performance.</li>
</ul>

This is not financial advice. Always do your own research.